Search results
Results from the WOW.Com Content Network
Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES). [5] It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.
Treat an asthma attack by visiting the hospital. Every year, more than 1.6 million Americans wind up in the emergency room because of an asthma attack, according to the CDC.If your attack is so ...
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems. [5] Safety in pregnancy and breastfeeding is unclear. [ 6 ] Fluticasone, a corticosteroid , works by decreasing inflammation while salmeterol, a long-acting beta-adrenoceptor agonist (LABA), works by activating beta-2 adrenergic receptors .
In order to achieve foundation trust status, NHS trusts have to pass a variety of tests, which have changed over time. In 2003 only trusts with three stars from the Commission for Health Improvement were eligible for foundation status. In that year Aintree Hospitals, Essex Rivers Healthcare, Newcastle upon Tyne Hospitals and Walsall Hospitals ...
The carbon footprint of blue inhalers is being compared to a lengthy car trip in advice released to asthma patients as British doctors are told to switch out the sprays for a more effective treatment.
Asthma + Lung UK (formally Asthma and Lung UK) is a British charity based in London, England. It focuses on respiratory health, in particular asthma and lung disease. [2] [3] The organisation was formed in January 2020 as Asthma UK and the British Lung Foundation Partnership as a result of a merger between Asthma UK and the British Lung Foundation.
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).